AnaptysBio Zukünftiges Wachstum
Future Kriterienprüfungen 1/6
AnaptysBioDer Gewinn des Unternehmens wird voraussichtlich um 15.2% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 18.4% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich zurückgehen.
Wichtige Informationen
-15.2%
Wachstumsrate der Gewinne
-0.05%
EPS-Wachstumsrate
Biotechs Gewinnwachstum | 27.1% |
Wachstumsrate der Einnahmen | 18.4% |
Zukünftige Eigenkapitalrendite | n/a |
Analystenabdeckung | Good |
Zuletzt aktualisiert | 03 Nov 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
AnaptysBio: Too Risky, Especially After GSK Drops Its Related Programs
Nov 01AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point
Aug 15AnaptysBio: Interesting Prospects, But Wait For The Dip (Rating Downgrade)
Jul 08News Flash: Analysts Just Made A Captivating Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts
May 22Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates
May 12Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?
Feb 22Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation
Oct 10AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Trimmed Their Revenue Forecasts By 12%
May 24Is AnaptysBio (NASDAQ:ANAB) In A Good Position To Deliver On Growth Plans?
Apr 27Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation
Jan 10AnaptysBio benefits from results of GSK mid-stage Jemperli combo lung cancer trial
Oct 05Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher
Sep 14AnaptysBio sells royalties from GSK-partnered Zejula for $45M
Sep 12AnaptysBio (NASDAQ:ANAB) Is In A Good Position To Deliver On Growth Plans
Sep 01AnaptysBio skin condition candidate fails mid-stage trial; shares down 16%
Aug 31AnaptysBio GAAP EPS of -$1.15 misses by $0.14, revenue of $1.21M misses by $4.4M
Aug 08Some AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Made A Major Cut To Next Year's Estimates
May 10Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation
Mar 16AnaptysBio's (NASDAQ:ANAB) Performance Is Even Better Than Its Earnings Suggest
Nov 11AnaptysBio (NASDAQ:ANAB) Is In A Strong Position To Grow Its Business
Jul 28Upgrade: Analysts Just Made A Dazzling Increase To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts
May 09AnaptysBio EPS beats by $0.03, beats on revenue
May 04Gewinn- und Umsatzwachstumsprognosen
Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
---|---|---|---|---|---|
12/31/2026 | 39 | -252 | -285 | -240 | 9 |
12/31/2025 | 32 | -223 | -162 | -201 | 12 |
12/31/2024 | 34 | -189 | -17 | -113 | 12 |
6/30/2024 | 30 | -170 | -130 | -129 | N/A |
3/31/2024 | 23 | -163 | -134 | -133 | N/A |
12/31/2023 | 17 | -164 | -122 | -121 | N/A |
9/30/2023 | 15 | -148 | -98 | -97 | N/A |
6/30/2023 | 13 | -144 | -79 | -78 | N/A |
3/31/2023 | 11 | -137 | -78 | -77 | N/A |
12/31/2022 | 10 | -129 | -74 | -74 | N/A |
9/30/2022 | 4 | -135 | -88 | -88 | N/A |
6/30/2022 | 24 | -108 | -78 | -77 | N/A |
3/31/2022 | 53 | -76 | -45 | -44 | N/A |
12/31/2021 | 63 | -58 | -47 | -46 | N/A |
9/30/2021 | 122 | 8 | 15 | 17 | N/A |
6/30/2021 | 101 | -9 | 5 | 7 | N/A |
3/31/2021 | 71 | -30 | -23 | -22 | N/A |
12/31/2020 | 75 | -20 | -15 | -14 | N/A |
9/30/2020 | 18 | -74 | -68 | -68 | N/A |
6/30/2020 | 18 | -81 | -73 | -73 | N/A |
3/31/2020 | 23 | -84 | -69 | -69 | N/A |
12/31/2019 | 8 | -97 | -70 | -70 | N/A |
9/30/2019 | 5 | -94 | -67 | -66 | N/A |
6/30/2019 | 10 | -79 | -60 | -59 | N/A |
3/31/2019 | 5 | -69 | -53 | -52 | N/A |
12/31/2018 | 5 | -62 | -50 | -49 | N/A |
9/30/2018 | 8 | -52 | -42 | -41 | N/A |
6/30/2018 | 3 | -45 | -31 | -30 | N/A |
3/31/2018 | 10 | -34 | N/A | -24 | N/A |
12/31/2017 | 10 | -30 | N/A | -19 | N/A |
9/30/2017 | 10 | -27 | N/A | -20 | N/A |
6/30/2017 | 13 | -19 | N/A | -19 | N/A |
3/31/2017 | 12 | -15 | N/A | -15 | N/A |
12/31/2016 | 17 | -4 | N/A | -9 | N/A |
9/30/2016 | 18 | -4 | N/A | -6 | N/A |
6/30/2016 | 19 | -4 | N/A | -5 | N/A |
3/31/2016 | 18 | -6 | N/A | -9 | N/A |
12/31/2015 | 18 | -5 | N/A | -10 | N/A |
9/30/2015 | 17 | -2 | N/A | -6 | N/A |
6/30/2015 | 19 | 0 | N/A | -4 | N/A |
3/31/2015 | 18 | 1 | N/A | -3 | N/A |
12/31/2014 | 16 | 0 | N/A | 15 | N/A |
12/31/2013 | 5 | -6 | N/A | -6 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: ANAB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: ANAB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: ANAB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: ANABDie Einnahmen des Unternehmens (18.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).
Hohe Wachstumseinnahmen: ANABDie Einnahmen des Unternehmens (18.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ANAB in 3 Jahren voraussichtlich hoch sein wird